Drug shortages dominate 2011 headlines

Ask average consumers to identify the biggest trend in pharmaceuticals, and they'd likely come back with one word: Shortages. Supply problems affected everything from oncology drugs to anesthetics. The former made headlines because hundreds of cancer patients had their treatments delayed or revamped. The latter, because U.S. death-penalty states couldn't get the drugs used in executions.

More drugs ran short in 2011 than ever before, thanks to a variety of manufacturing problems and financial challenges. Drug plants ran afoul of FDA manufacturing practices, hampering production. The number of suppliers for certain low-margin generics dwindled, sometimes to a single manufacturer. Raw materials for some drug ingredients ran short. Rival drugmakers tried to ramp up output to fill the supply gaps, but couldn't boost production overnight.

The shortages grew so acute—and so public—that President Obama signed an executive order demanding that the FDA, in effect, "do something." Lawmakers proposed new rules. The Government Accountability Office concluded that the only way to address drug scarcity would be to give the FDA more power. The agency could then require drugmakers to raise red flags when they hit snags that could result in shortages—and to demand action to prevent potential shortages or fix existing ones. Whether Congress would actually grant such powers is another question.

Special Report: Top drug shortages by treatment category

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.